The Atypical HUS Foundation

TRALI - Precautionary Note about Infusion of Blood Products

"Male donor plasma ONLY" was marked on both Hunter and Skyler's medical records. Hunter had at least one, probably two, instances of TRALI - or transfusion-related lung injury. Each time requiring a stay in the pediatric intensive care unit, Hunter was given a slim chance of survival. Complicating Hunter's aHUS issues, the TRALI events created major physical setbacks that required going back to plasmapheresis after enjoying a period of relative calm for aHUS activity. After the second event, when TRALI was offically recognized by our medical team, Hunter actually had his own designated shelf at our hospital's Blood Bank, with specially ordered male blood products. It all began when Hunter was a half-hour into a plasma infusion, and had rapid onset respiratory failure due to an immunologic reaction involving antibodies in a unit of FFP. Apparently, female donors who have had multiple children create antibodies in their plasma, retaining these for life and therefore becoming high-risk donors for causing a TRALI reaction. Transfusion-related acute lung injury is a poorly understood, life-threatening complication of blood transfusion. The most common transfused blood product implicated in cases of death due to TRALI has been fresh frozen plasma (FFP)
The National Blood Service of the United Kingdom in 2004 mandated that plasma from female donors not be transfused but rather fractionated into derivatives. In the past two years, the U.S. has begun to follow suit and has already completed the change over to "male plasma donors only" at various locales in America. Given the high numbers of plasma units Hunter needed for infusions/plasmapheresis, we were informed it was a wonder that life-threatening TRALI events had not occurred with more frequency.
It is likely that your hospital now only receives "male donor plasma" as a matter of course. Still, it is a simple thing to give a copy of this article to your child's doctor and ask, "Our plasma is male donor only plasma, right?".

What is TRALI?  (An Overview)

TRALI, or transfusion related acute lung injury, is a serious complication which can occur within the first six hours following a  transfusion of blood products. Transfusion-related acute lung injury is an uncommon syndrome that is due to the presence of leukocyte antibodies in transfused plasma. TRALI is believed to occur in approximately one in every 5000 transfusions of blood products.

TRALI has been associated with patient infusions of plasma components such as fresh frozen plasma (FFP) and platelets,  though cases also have been reported with packed red blood cells (RBC) since there is some residual plasma remains in the packed cells.

 In recent years, the incidence of TRALI has decreased with modified transfusion practices, but it remained the leading cause of transfusion-related fatalities in the United States from 2008-2012.  The FDA issued a warning to physicians regarding TRALI (link below) as “Transfused plasma (from any component source) may also contain antibodies that cross-react with platelets in the recipient, producing usually mild forms of posttransfusion purpura or platelet aggregation after transfusion” 

Please consult with your physician regarding your concerns about treatment options and issues.

 

Research  and other TRALI Resources:

ASH BLOOD Jourmal:  http://bloodjournal.hematologylibrary.org/content/105/6/2266

NIH  National Institutes of Health http://www.ncbi.nlm.nih.gov/pubmed/15938734

FDA Cautions Physicians about TRALI

"This is to alert you to the possibility that patients who receive blood products, particularly plasma-containing products, may be at risk for Transfusion Related Acute Lung Injury (TRALI), a serious pulmonary syndrome that can lead to death if not recognized and treated appropriately. Even small amounts of plasma in packed red blood cells may induce TRALI. Recognition of symptoms and immediate treatment are imperative." 

FMI read the full text at http://www.fda.gov/biologicsbloodvaccines/safetyavailability/bloodsafety/ucm095556.htm

Views: 115

Attachments:

Reply to This

Replies to This Discussion

Further information:
Attachments:
wow... i had no idea thats why they only use male plasma ouor doc is pretty on top of it but i hope they only use male plasma chloe has recieved over 130 units in the last year
I didn't know that. Anna keeps receiving Plasma and it is going well wile she takes prednisone with it. We don't like that medicine, but it is only way to keep her from any reactions. I will try to find out if they use precaution on it.
Thanks
Hi Sveta,
Unfortunately, TRALI is such an overwhelming event that premedication is of little help. Hunter was premedicated both times and perhaps it allowed us a couple of minutes extra to rush him to the Pediatric Intensive Care Unit, but it was still touch and go for days. It is unnecessary to risk such a life-threatening event! Just ask your doctor these questions:
*Is this unit of plasma clearly marked "male donor plasma"?
*If not, has our blood bank region totally changed over to the new standard - male donor only plasma?
*Could you please call the hospital blood bank to check if this particular unit of plasma is male donor only?
As the attached articles clearly state, TRALI is an under-reported cause of death in patients getting large volumes of plasma (FFP). It's really easy to safeguard your child against this issue... please take those few moments to check with your doctor and hand him/her one of these TRALI articles!



Linda Burke said:
Svetlana Finley said:
I didn't know that. Anna keeps receiving Plasma and it is going well wile she takes prednisone with it. We don't like that medicine, but it is only way to keep her from any reactions. I will try to find out if they use precaution on it.
Thanks

Reply to Discussion

RSS

IN REGARD TO MEMBERSHIP REQUESTS

To ensure proper processing of your membership, please make sure to set your email filters to accept emails, from info@atypicalhus.org.

The Atypical HUS Foundation is an all-volunteer organization. Please allow at least 72 hours for an email response confirming your membership request.  If you do not receive an email, please check your spam folder or email directly to info@atypicalhus.org

Membership is open to patients, family, friends, caregivers research and medical personnel.

WELCOME - JOIN US!

The Atypical HUS Foundation encourages patients and investigators to share information and explore options/resources as we work together to gain insight into this rare complement disorder. By increasing contact opportunities with researchers and medical personnel interested in helping the aHUS community, our stories foster a better understanding of atypical hemolytic uremic syndrome.

Sharing information, inspiration and support for one another, we seek to gather together people and knowledge as we strive to improve the lives of patients and families dealing with a diagnosis of aHUS.


NEW DIAGNOSIS OF aHUS?
Be proactive! Get the medical basics of aHUS, what lab values to monitor, and areas of concern...check out the "aHUS Bootcamp" and "About aHUS" tabs at the top of this page!
If your doctor has never treated a case of aHUS, please print out our 'Doc to Doc Registry' and ask him/her to contact a physician versed in the complexities of aHUS and new options for 2011 genetic testing and treatment.

************************

NOTE: Our 'Send a Message" function on each Member's page allows for private discussion of personal content. As with any social network, be cautious about giving personal contact information (home email info, phone number) until you have an established relationship with another person, organization, or associated website.

 

Did you know...

CFH (Serum Complement Factor H) is a regulatory protein. The secreted protein product of CFH consists of 20 repetitive units named "short consensus repeats" or SCRs (each approximately 60 amino acids). In patients with aHUS the last 5 "pearls" in the twenty pearl strand protein, SCR16 - SCR20, should bind to protect cells but do not- they are defective in one or more of the last 5 SCR locations. If they cannot bind or stick to the kidney to protect that tissue, the platelets clump into clots that affect the glomeruli of the kidney -potentially causing acute renal failure.
  
• • • • • • • • • • • •
  
It is estimated that there are about 2 cases of aHUS in the U.S. per 1,000,000 of population, and about 60% of aHUS patients are diagnosed as children. The condition is potentially life threatening, and either can be chronic or can recur at intervals.
  
more factoids...

Help us fight the battle

Your donation of $295.for an aHUS pearl bracelet will directly fund research to help aHUSpatient and their families. Each bracelet has an appraised value of $925, and is offered with your gift of $295. Note:  For shipping outside the USA, please add $25. to cover international shipping costs.

(Note: Bracelets do not qualify as tax deductible donations under IRS regulations.)

Normally, aHUS pearl bracelets to be made-to-order and as such expect a 4 to 6 week window before your custom bracelet is shipped.  In a rush?  Contact info@atypicalhus.org with your request and details.

 

 Donations of a specific dollar amount are welcome-every dollar will help aHUS research efforts supported by The Atypical HUS Foundation at www.atypicalhus.org.


Donations may be made via credit card or Paypal. If you prefer, checks made payable to The Atypical HUS Foundation may be mailed to:

The Atypical HUS Foundation
C/O Deborah Lewis
PO Box 333
Barnhart, MO 63012


For pearl bracelet orders, please allow extra time for processing checks. Questions about aHUS donations? Please email info@atypicalhus.org

Badge

Loading…

© 2017   Created by Deborah Lewis.   Powered by

Badges  |  Report an Issue  |  Terms of Service